Genetic Diagnostics & Therapy 21 LTD
Medicine of the future
Our Aim
"Genetic Diagnostics & Therapy 21" Ltd. operates across various countries with the purpose of developing innovative gene therapy drugs and groundbreaking genetic diagnostic technologies.
This is accomplished by attracting specialists and by forming an international team focused at achieving results in consortiums with research groups and biotechnological companies.
How I Can
Help You
Our Focus Areas
Our developments:
A neat solution - non-viral gene therapy DNA vectors of "VTvaf17" and "GDTT1.8NAS" series for cell transfection in the manufacture of personalized cellular products and creation of genetic drugs.
We have developed innovative gene therapy DNA vectors of "VTvaf17" and "GDTT1.8NAS" series. Key differences of these DNA-vectors from the existing plasmid vectors:
-
Safe to use due to absence of antibiotic resistance genes and sequences of viral genomes in the vector;
-
Minimal size of the vector ensuring efficient delivery of therapeutic genes
-
Manufacturability (up to 200 mg of DNA from 1 litre of the bacterial culture)
Type 2 Diabetes Treatment
Development safe and effective drugs for the treatment of type 2 diabetes mellitus.
The project includes three independent areas at different
stages of development:
-
“Neogliptin” – a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, an original drug that is at the final stage of preclinical trials. The intended use of the drug is T2DM therapy. Previous preclinical trials in vitro and in vivo have confirmed the effectiveness and safety of Neogliptin, putting it on a par with competing drugs from the leading pharmaceutical companies;
-
“Genopepta” – a gene therapy drug based on a own non-viral DNA vector. The DNA vector carries a structural element encoding glucagon-like peptide-1 (GLP-1), which is involved in the control of blood sugar levels. The intended use of the drug is to treat T2DM and counteract obesity.
-
“Glicobact” – a medicinal product in the form of intestinal bacteria in an enteric soluble shell (recombinant lactobacillus based on native line of human lactobacillus) producing GLP-1. The intended use of the drug is T2DM therapy and anti-obesity medication.
